Antiliver Fibrosis Formula of Fuzheng Huayu Alleviates Inflammatory Response

Figure 1

FZHY inhibited iNOS in inflammatory macrophages and mice CCl₄-treated liver tissues. (a) Cell viability was determined by MTT assay. (b) NO production was evaluated by Griess reaction following incubation with model group (LPS/IFN-γ), control group (vehicle control), and 25–200 μg/ml FZHY treatment groups for 24 h. (c) iNOS mRNA in each group from cells was assessed by qPCR. (d) iNOS protein in each group from cells was assessed by western blotting. (e) iNOS mRNAs from liver tissues were assessed by qPCR. (f) iNOS proteins from liver tissues were assessed by western blot. Values are presented as the mean ± SD (standard deviation) from at least three replicates. (C) Vehicle control of macrophages or control group mice; (M) model group (stimulation by LPS at 100 ng/mL and IFN-γ at 100 ng/mL or CCl₄ induced mice); 1400W (an iNOS selective inhibitor at 50 μM); 100: FZHY treatment group at the concentration of 100 μg/mL on macrophages; 200: FZHY treatment group at the concentration of 200 μg/mL on macrophages; FZHY : FZHY treatment group at the dosage of 5.6 g/kg/day for 6-week administration on CCl₄-induced mice; versus C group; versus C group; versus M group; versus M group.

(a)

(b)

(c)

(d)

(e)

(f)